Bilen MA et al (2018) Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab. Clin Genitourin Cancer 16:e563–e575. https://doi.org/10.1016/j.clgc.2017.12.015

Article  PubMed  PubMed Central  Google Scholar 

Choueiri TK et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829–841. https://doi.org/10.1056/NEJMoa2026982

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corti F et al (2021) The pan-immune-inflammation value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer 150:155–167. https://doi.org/10.1016/j.ejca.2021.03.043

Article  CAS  PubMed  Google Scholar 

De Giorgi U et al (2019) Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin Cancer Res 25:3839–3846. https://doi.org/10.1158/1078-0432.CCR-18-3661

Article  PubMed  Google Scholar 

Dudani S et al (2020) Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): new and updated benchmarks of clinical outcomes. J Clin Oncol 38:5063–5063. https://doi.org/10.1200/JCO.2020.38.15_suppl.5063

Article  Google Scholar 

Dymicka-Piekarska V, Koper-Lenkiewicz OM, Zinczuk J, Kratz E, Kaminska J (2021) Inflammatory cell-associated tumors. not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment the unique role of tumor associated platelets (TAPs). Cancer Immunol Immunother 70:1497–1510. https://doi.org/10.1007/s00262-020-02758-7

Article  CAS  PubMed  Google Scholar 

Fuca G et al (2020) The pan-immune-Inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the valentino and TRIBE first-line trials. Br J Cancer 123:403–409. https://doi.org/10.1038/s41416-020-0894-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fuca G et al (2021) The pan-immune-inflammation value in patients with metastatic melanoma receiving first-line therapy target. Oncol 16:529–536. https://doi.org/10.1007/s11523-021-00819-0

Article  Google Scholar 

Gambichler T, Said S, Abu Rached N, Scheel CH, Susok L, Stranzenbach R, Becker JC (2022) Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-022-03929-y

Article  PubMed  PubMed Central  Google Scholar 

Gao Y et al (2019) Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. J Cancer 10:3188–3196. https://doi.org/10.7150/jca.30281

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia-Rojo D, Prera A, Munoz-Rodriguez J, Oliva JC, Dominguez A, Prats J (2021) Prognostic value of lymphocyte-to-monocyte ratio previously determined to surgery in patients with non-metastatic renal cell carcinoma: a systematic review and a prisma-compliant meta-analysis. Med (Baltimore) 100:e24152. https://doi.org/10.1097/MD.0000000000024152

Article  CAS  Google Scholar 

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899. https://doi.org/10.1016/j.cell.2010.01.025

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heng DY et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799. https://doi.org/10.1200/JCO.2008.21.4809

Article  CAS  PubMed  Google Scholar 

Hizal M et al (2020) Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish oncology group study). J Oncol Pharm Pract 26:1583–1589. https://doi.org/10.1177/1078155219900908

Article  CAS  PubMed  Google Scholar 

Jeyakumar G et al (2017) Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy J Immunother. Cancer 5:82. https://doi.org/10.1186/s40425-017-0287-5

Article  Google Scholar 

Lalani AA et al (2018) Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer 6:5. https://doi.org/10.1186/s40425-018-0315-0

Article  PubMed  PubMed Central  Google Scholar 

Laubli H, Spanaus KS, Borsig L (2009) Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 114:4583–4591. https://doi.org/10.1182/blood-2008-10-186585

Article  CAS  PubMed  Google Scholar 

Ligorio F et al (2021) The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers (Basel). https://doi.org/10.3390/cancers13081964

Article  Google Scholar 

Liu J et al (2019) Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal 33:e22964. https://doi.org/10.1002/jcla.22964

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. https://doi.org/10.1038/nature07205

Article  CAS  PubMed  Google Scholar 

Motzer RJ et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813. https://doi.org/10.1056/NEJMoa1510665

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290. https://doi.org/10.1056/NEJMoa1712126

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer R et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289–1300. https://doi.org/10.1056/NEJMoa2035716

Article  CAS  PubMed  Google Scholar 

Na N, Yao J, Cheng C, Huang Z, Hong L, Li H, Qiu J (2016) Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors. Oncotarget 7:44039–44046. https://doi.org/10.18632/oncotarget.9836

Article  PubMed  PubMed Central  Google Scholar 

National comprehensive cancer network-kidney cancer (2021). https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed 21 Jul2021

Nishiyama N et al (2020) The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study. BMC Urol 20:110. https://doi.org/10.1186/s12894-020-00679-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Posadas EM, Limvorasak S, Figlin RA (2017) Targeted therapies for renal cell carcinoma. Nat Rev Nephrol 13:496–511. https://doi.org/10.1038/nrneph.2017.82

Article  PubMed  Google Scholar 

Rebuzzi SE et al (2020) Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: preliminary results of the Meet-URO 15 (I-BIO-REC) study. J of Clin Oncol 38:751–751. https://doi.org/10.1200/JCO.2020.38.6_suppl.751

Article  Google Scholar 

Susok L, Said S, Reinert D, Mansour R, Scheel CH, Becker JC, Gambichler T (2022) The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-021-03878-y

Article  PubMed  PubMed Central  Google Scholar 

Teishima J et al (2020) Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Can Urol Assoc J 14:E582–E587. https://doi.org/10.5489/cuaj.6413

Article  PubMed  PubMed Central  Google Scholar 

Templeton AJ et al (2016) Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur Urol 70:358–364. https://doi.org/10.1016/j.eururo.2016.02.033

Article  PubMed  Google Scholar 

Vicente Conesa MA, Garcia-Martinez E, Gonzalez Billalabeitia E, Chaves Benito A, Garcia Garcia T, Vicente Garcia V, de la Pena FA (2012) Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. Breast 21:468–474. https://doi.org/10.1016/j.breast.2011.11.002

Article  PubMed  Google Scholar 

Wang Q, Zhu D (2019) The prognostic value of systemic immune-inflammation index (SII) in patients after radical operation for carcinoma of stomach in gastric cancer. J Gastrointest Oncol 10:965–978. https://doi.org/10.21037/jgo.2019.05.03

Article  PubMed  PubMed Central  Google Scholar 

Wu L, Saxena S, Awaji M, Singh RK (2019) Tumor-associated neutrophils in cancer: going pro. Cancers (Basel). https://doi.org/10.3390/cancers11040564

Article  PubMed  PubMed Central  Google Scholar 

Xu JX et al (2017) FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis. Oncologist 22:311–317. https://doi.org/10.1634/theoncologist.2016-0476

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yasar HA et al (2020) The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. J Oncol Pharm Pract 26:1110–1116. https://doi.org/10.1177/1078155219883004

Article  CAS  PubMed